Personalis Stock

Personalis FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Personalis (PSNL) as of Aug 1, 2026 is 97.76 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 57.52 % — a change of 69.96% (higher).

FCF Conversion

97.76 %

YoY

69.96%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Personalis is 2026 97.76 % . FCF Conversion Rate (FCF/EBITDA) of Personalis was 2025 57.52 % . It decreases by 69.96% higher compared to the previous year.
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

FCF Conversion Rate (FCF/EBITDA) of Personalis is 97.76 % in 2026.

Access this data via the Eulerpool API

Cash Flow — Personalis

All Key Metrics — Personalis